Clinical trial · Interventional
Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL
Chemoimmunotherapy With Obinutuzumab, Ifosfamide, Carboplatin and Etoposide (O-ICE) in Children, Adolescents and Young Adults With Recurrent Refractory CD20+ Mature B-NHL
NCT02393157CI-TRIAL-00093313O-ICErecruitingPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to determine the safety of administering obinutuzumab as a single agent alone and in combination with ifosfamide, carboplatin, and etoposide (ICE) chemotherapy and determine the response rate of this treatment for children, adolescents and young adults (CAYA) with relapsed CD20 positive B-cell Non-Hodgkin Lymphoma (B-NHL).
Conditions
Conditions (6)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Burkitt Lymphoma | Burkitt Lymphoma | ONTOLOGY_EXACT | 0.90 |
| CD20+ Lymphoblastic Lymphoma | — | UNRESOLVED | — |
| Diffuse Large B-Cell Lymphoma | Diffuse Large B-Cell Lymphoma | CURATED_BROADER | 0.80 |
| Follicular Lymphoma, Grade III | Grade 3 Follicular Lymphoma | ALIAS | 0.90 |
| Non-Hodgkin Lymphoma | Non-Hodgkin Lymphoma | ONTOLOGY_EXACT | 0.90 |
| Primary Mediastinal B-cell Lymphoma | Primary Mediastinal Large B-Cell Lymphoma | ALIAS | 0.90 |
Interventions
Interventions (5)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Carboplatin | Drug | Carboplatin | ALIAS |
| Etoposide | Drug | Etoposide | ALIAS |
| Ifosfamide | Drug | Ifosfamide | ALIAS |
| Liposomal ARA-C | Drug | — | UNRESOLVED |
| Obinutuzumab | Drug | Obinutuzumab | ALIAS |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Central Nervous System (CNS) Negative
- description
- All patients will receive 4 doses of obinutuzumab on days -14, -10, -6 and -2. Patients without CNS involvement will receive one dose of Liposomal cytarabine for CNS prophylaxis on day -13. Dexamethasone will be given for 5 days with each Liposomal cytarabine dose starting one day prior to the Liposomal cytarabine. Dexamethasone 0.15 mg/kg/dose (max 4mg) IV BID will be given days -14 to -10. Following completion of the Prephase (or at the first sign of progressive disease), all patients will proceed to cycle 1 of O-ICE. O-ICE chemotherapy is given in 21-day (3-week) cycles. Three weekly doses of obinutuzumab will be given days -2 (during the prephase), +6 and +13. Patients will receive ICE chemotherapy (ifosfamide-carboplatin-etoposide) administered on Days 0-2 of Cycle 1.
- interventionNames
- Drug: Obinutuzumab
- Drug: Liposomal ARA-C
- Drug: Ifosfamide
- Drug: Carboplatin
- Drug: Etoposide
- type
- EXPERIMENTAL
- label
- CNS Positive
- description
- All patients will receive 4 doses of obinutuzumab on days -14, -10, -6 and -2. Patients with positive CSF prior to enrollment will receive treatment with two doses of Liposomal cytarabine during the prephase portion of therapy. Liposomal cytarabine will be given intrathecally on days -13 and -5. Dexamethasone will be given for 5 days with each Liposomal cytarabine dose starting the day prior to the Liposomal cytarabine. Dexamethasone will be given days -14 to -10 and days -6 through -2. Following completion of the Prephase (or at the first sign of progressive disease), all patients will proceed to cycle 1 of O-ICE. O-ICE chemotherapy is given in 21-day (3-week) cycles. Three weekly doses of obinutuzumab will be given days -2 (during the prephase), +6 and +13. Patients will receive ICE chemotherapy (ifosfamide-carboplatin-etoposide) administered on Days 0-2 of Cycle 1.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 3 Years
- Maximum age
- 31 Years
Show eligibility criteria text
Inclusion Criteria: * Patients in first relapse or primary induction failure CD20 positive B-cell leukemia/lymphoma including: * Diffuse Large B-Cell Lymphoma * Burkitt Lymphoma * High Grade B-cell Lymphoma: Not Otherwise Specified (NOS) * Primary mediastinal B-cell lymphoma (PMBL) * CD20+ B-lymphoblastic lymphoma * Follicular lymphoma, Grade III * Karnofsky ≥ 60% for patients \> 16 years of age and * Lansky ≥ 60 for patients ≤ 16 years of age. * Myelosuppressive chemotherapy: Must not have received within 2 weeks of entry onto this study. * Patients may not have received prior therapy with obinutuzumab (GA101) * Radiation Therapy (XRT): Date of receiving prior XRT must be \> 2 weeks for local palliative XRT (small port); \> 6 months must have elapsed if prior craniospinal XRT or if \> 50% radiation of pelvis; \> 6 weeks must have elapsed if other substantial bone marrow radiation. * Steroids: Patients may have received prior steroid treatment, but not started greater than 7 days prior to initiation of protocol therapy. * Adequate organ function. Exclusion Criteria: * Patients with newly diagnosed, previously untreated B-NHL. * Known congenital or acquired immune deficiency. * Prior solid organ transplantation. * Prior allogeneic stem cell transplant within 60 days or active acute Graft-vs-Host-Disease (GVHD) grade 3 or higher. * History of grade 4 anaphylactic reactions to humanized or murine monoclonal antibodies * Uncontrolled hepatitis B and/or C infection
References
Publications (0)
Data not yet available
No reference posted for this study.